The study’s scientific inquiry centered around more than 400 pregnant participants recruited from a maternity hospital setting. Researchers implemented an observational design, capturing real-time self-reported data on mental imagery related to three key vaccines: for whooping cough, influenza, and COVID-19. Each participant was asked not only to convey their perceived risk of contracting these diseases but also to describe any spontaneous mental images evoked by both the diseases themselves and the vaccinations offered as protection. This approach bridges cognitive psychology with immunization behavior, providing a nuanced closer look at the mental processes driving health choices during pregnancy.

Crucially, the study differentiated between the emotional tone of these mental images. Negative images commonly involved distressing scenarios such as harm or side effects attributed to vaccines. Positive imagery, in contrast, included hopeful and protective visuals, such as imagining antibodies acting as a shield passed from mother to fetus via the umbilical cord. These contrasting mental narratives revealed predictive relationships with vaccine hesitancy and actual vaccine uptake patterns. Women experiencing negative imagery generally exhibited greater reluctance to accept vaccines, especially for whooping cough and influenza, if they were yet to be vaccinated, highlighting the emotive underpinning of vaccine decisions.

What emerges from this research is a layered understanding that mental imagery operates independently of broad attitudinal assessments. Even after controlling for general pro- or anti-vaccination sentiments, the unique influence of these emotional mental representations persisted. This finding underscores that vaccine decision-making is not merely a rational weighing of risks and benefits but also a cognitive-emotional experience in which vivid, spontaneous images function as implicit heuristics or affective cues guiding behavior. This opens an avenue for public health messaging to harness cognitive psychology tools aimed at reshaping these mental images towards positivity.

When the researchers matched mental imagery profiles with actual vaccination records obtained from official immunization databases post-delivery, a compelling pattern was noted. Pregnant women who conjured positive, protective mental images were significantly more likely to have received the whooping cough vaccine, and furthermore, they tended to receive it earlier in their pregnancy. This temporal correlation suggests that positive mental imagery may not only encourage vaccine uptake but may also influence the timeliness—a critical factor for maximizing maternal and neonatal protection.

The uptake rates among the cohort reflected real-world challenges in maternal immunization. Whooping cough vaccination reached an encouraging coverage rate of 82.1%, yet influenza vaccination lagged at 60.1%, with COVID-19 vaccination alarmingly low at only 7.2%. These discrepancies highlight multifaceted barriers beyond vaccine access, pointing toward psychological influences that this innovative research addresses head-on. The potential to intervene at the level of mental imagery provides a promising new vector to counteract suboptimal vaccine adoption during pregnancy.

Leading author Dr. Julie Ji, from the University of Plymouth and the University of Western Australia, encapsulated the study’s significance. She emphasized that pregnancy constitutes a unique psychologically sensitive period where health decisions carry amplified emotional weight, demanding an approach that goes beyond addressing rational concerns alone. “Our findings spotlight mental imagery as a tangible psychological mechanism influencing both feelings toward vaccines and tangible vaccination behavior during pregnancy,” she noted, advocating for targeted interventions rooted in cognitive-emotional frameworks.

This study is situated within a broader scientific dialogue concerning the cognitive, emotional, and motivational potency of mental imagery. Researchers at the University of Plymouth have been at the forefront of demonstrating how vividly imagined mental scenes can make both recollections and predictions feel strikingly real, with substantial power to modulate emotions, beliefs, and consequently behaviors. Applying this cognitive science perspective to vaccine hesitancy is not only novel but portends practical applications informed by decades of mental health research exploring imagery’s therapeutic modulation.

The interdisciplinary nature of the research team—spanning psychology, midwifery, infectious diseases, pediatrics, and social sciences—was instrumental in facilitating a holistic exploration that marries laboratory psychological constructs with clinical and population-level data. Their collaborative synergy enabled the collection of verified vaccination records, ensuring behavioral outcomes were precisely measured rather than relying on self-report alone. This methodological rigor enhances the reliability of the study’s conclusions, differentiating it from prior work predicated solely on attitudinal or survey data.

Funding was provided by prominent organizations including the Telethon Channel 7 Western Australia Child Research Fund, underscoring the project’s alignment with broader public health goals aimed at optimizing child and maternal health outcomes through enhanced vaccine uptake. The translational potential of these findings is vast, situating mental imagery not just as a theoretical construct but as a modifiable psychological target for interventions like visualization exercises or guided imagery embedded within antenatal care protocols.

Looking ahead, the research team is exploring actionable strategies to harness positive mental imagery in ways that facilitate informed, confident vaccination decisions among pregnant women. Such strategies might include narrative-based communications, virtual reality simulations, or counseling techniques designed to evoke and reinforce protective mental scenes. This represents an exciting frontier in vaccine advocacy, moving beyond information dissemination into the realm of the emotional-cognitive psyche where decision-making mechanisms truly unfold.

The implications of this research extend beyond pregnancy to broader vaccination campaigns and public health initiatives. Understanding how mental images influence vaccine hesitancy offers a fresh psychological lens through which to reframe interventions, potentially increasing their resonance and effectiveness. In an era where vaccine misinformation and emotional resistance threaten global health, leveraging the science of mental imagery could become a key innovation in promoting vaccine confidence at individual and community scales.

Ultimately, these findings compel a reconceptualization of vaccine hesitancy during pregnancy from a purely informational deficit to a nuanced psychological phenomenon. Future research and clinical practice would benefit from integrating mental imagery-focused assessments and interventions, providing pregnant women with emotional tools that not only inform but inspire protective actions. This pioneering work stands as a testament to the power of interdisciplinary research and cognitive science in shaping the future of preventive medicine and maternal-child health.

Subject of Research: People
Article Title: Vaccine hesitancy and uptake during pregnancy: investigating the role of emotional mental imagery
News Publication Date: 30-Apr-2026
Web References: http://dx.doi.org/10.1016/j.socscimed.2026.119302
References:
Image Credits:
Keywords: Pregnancy, Vaccine hesitancy, Mental imagery, Maternal health, Cognitive psychology, Vaccine uptake, Public health, Emotional cognition, Immunization behavior, Preventive medicine, COVID-19 vaccines, Influenza vaccines, Whooping cough vaccine

The context of the study emerges from the widespread recommendation by public health authorities in the United States endorsing COVID-19 vaccination among pregnant individuals. Two vaccine types predominate these recommendations: messenger ribonucleic acid (mRNA) vaccines, which instruct the body’s cells to produce an antigen to elicit immunity, and protein subunit vaccines, which introduce fragments of the virus to stimulate immune defense. Both approaches have demonstrated safety profiles deemed compatible with any stage of pregnancy, safeguarding maternal and neonatal health outcomes against SARS-CoV-2 infection.

This multi-center prospective observational study, conducted from May 2024 to March 2025 and overseen by the Maternal-Fetal Medicine Units Network, meticulously analyzed neurodevelopmental outcomes in a cohort of 434 toddlers aged 18 to 30 months. The cohort was evenly divided between children whose mothers received at least one dose of an mRNA vaccine near or during pregnancy, and those whose mothers remained unvaccinated during the same timeframe. By capturing a diverse population across multiple clinical settings, the study offers robust generalizability to real-world scenarios.

To ensure methodological rigor, researchers employed stringent matching criteria, aligning vaccinated and unvaccinated subjects by factors such as delivery site, timing of birth, insurance status, and racial demographics. Furthermore, potential confounders were minimized by excluding cases of preterm birth before 37 weeks, multifetal gestations, and neonates presenting with significant congenital anomalies. These careful controls bolster the validity of the study’s conclusions by reducing bias and ensuring comparable baseline characteristics.

Neurodevelopmental health was evaluated through a comprehensive battery of standardized assessments. Principal among these was the Ages and Stages Questionnaire Version 3 (ASQ-3), a validated tool probing five domains critical to early childhood development: communication skills, gross motor abilities, fine motor coordination, problem-solving aptitude, and personal-social interaction. Complementing this, researchers utilized the Child Behavior Checklist, the Modified Checklist for Autism in Toddlers, and the Early Childhood Behavior Questionnaire to provide a multidimensional picture of cognitive and behavioral functioning.

The findings were unequivocal: there was no significant difference in the prevalence of neurodevelopmental delays, autism spectrum signs, or behavioral anomalies between the two groups. Dr. George R. Saade, a leading figure in maternal-fetal medicine and the senior investigator of the study, emphasized that these outcomes underscore the neurodevelopmental safety of receiving mRNA vaccines during the periconceptional and prenatal periods. This data lends much-needed reassurance amid vaccine hesitancy fueled by concerns of potential long-term neurologic effects on offspring.

Interestingly, the ability to match subjects on socio-economic and medical parameters ensured that the study controlled for confounding social determinants of health, which themselves can impact neurodevelopment. This methodological sophistication lends confidence that observed outcomes are directly attributable to maternal vaccination status rather than external socio-environmental factors, thereby strengthening the argument for vaccine safety.

This investigation was conducted under the auspices of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, reinforcing its scientific credibility and adherence to rigorous clinical research standards. It is also notable that the study was embedded within the highly respected National Institutes of Health (NIH) clinical trials network, facilitating adherence to gold-standard protocols and enhancing data reliability.

Dr. Brenna L. Hughes, a distinguished professor at Duke University who co-led the research, commented on the findings, highlighting their critical importance in dispelling myths and reinforcing vaccine advocacy. The absence of deleterious neurodevelopmental outcomes after prenatal mRNA COVID-19 vaccination addresses a major public health barrier by reassuring pregnant individuals and healthcare providers alike about the vaccine’s safety profile.

Given these impactful findings, healthcare practitioners specializing in obstetrics, pediatrics, and public health are likely to incorporate this evidence into clinical counseling. It empowers them to confidently recommend COVID-19 vaccination during pregnancy, thus enhancing protection not only for the expectant mother but also for the infant through potential passive immunity and mitigated risks of maternal infection.

Beyond immediate clinical implications, this study contributes substantively to the broader scientific discourse concerning vaccine safety during critical periods of immune and neural development. It sets a precedent for future vaccine safety monitoring and post-marketing surveillance, establishing a framework for addressing vaccine hesitancy with high-quality evidence.

In summary, this comprehensive study decisively corroborates that mRNA COVID-19 vaccines administered proximate to or during pregnancy are devoid of neurodevelopmental risks such as autism in early childhood. As global vaccination campaigns continue to evolve in the face of emerging SARS-CoV-2 variants, this research provides a robust foundation supporting the continued implementation of immunization strategies among pregnant populations worldwide.

Subject of Research: People
Article Title: Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months
News Publication Date: February 11, 2026
Web References: https://smfm2026.eventscribe.net/
References: Oral abstract #8 “Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months,” published in Pregnancy, February 2026 issue
Keywords: mRNA COVID-19 vaccine, pregnancy, neurodevelopment, autism, SARS-CoV-2, maternal vaccination, child development, observational study, Ages and Stages Questionnaire, vaccine safety, maternal-fetal medicine

Historically, the CDC’s immunization schedule has recommended COVID-19 vaccines during pregnancy based on extensive epidemiological data demonstrating that pregnant individuals infected with SARS-CoV-2 face elevated risks of severe illness and mortality compared to their non-pregnant counterparts. Moreover, evidence has consistently indicated that vaccination during pregnancy not only protects the mother but confers passive immunity to the newborn, reducing neonatal infection risks and associated complications. These findings have been integral to public health strategies aiming to mitigate the pandemic’s impact on vulnerable populations.

The recent policy reversal starkly contrasts with the prior scientific consensus. The CDC’s communications now state “No guidance/not applicable” regarding COVID-19 vaccines for pregnant women, essentially removing formal endorsement despite the persistence of scientific data supporting vaccine safety and efficacy in this demographic. This has sparked widespread controversy and prompted professional organizations, notably the American Academy of Pediatrics and other major medical groups, to file litigation challenging the policy and advocating for evidence-based decision-making.

At the crux of this debate is the public’s perception and understanding of vaccination during pregnancy. A recent comprehensive health survey conducted by the Annenberg Public Policy Center (APPC) in August 2025 highlights a notable reluctance among the U.S. adult population to recommend COVID-19 vaccines to pregnant individuals. Only 38% expressed willingness to recommend vaccination during pregnancy. This skepticism extends to safety perceptions; just 42% of survey respondents affirmed that mRNA COVID-19 vaccines are safe for pregnant women. Significantly, women of childbearing age (18-49 years) displayed higher levels of doubt, with only 36% affirming safety and 28% disbelieving the vaccine’s safety during pregnancy—figures that have worsened compared to earlier surveys in 2024.

These shifting attitudes may be partially attributed to conflicting messages from health authorities and the amplified discourse surrounding vaccine mandates and autonomy. The divergence between administrative stances and the prevailing body of peer-reviewed scientific literature has engendered confusion and hesitancy. This is particularly concerning given that pregnant women’s risk profiles for COVID-19 complications, including preterm birth, stillbirth, and severe respiratory illness, remain elevated without immunization. Systematic reviews of global data underscore the immunological benefits and safety profile of mRNA vaccines during all trimesters, a nuance that simplified policy directives may obscure.

Further dissection of the survey data reveals disparities in understanding specific vaccine benefits. While just over half (52%) recognize that vaccination reduces the risk of hospitalization due to COVID-19, among women aged 18-49 this awareness dips to 43%, reflecting a knowledge gap that could have adverse public health consequences. Similarly, only 51% acknowledged that vaccination mitigates complications affecting pregnancy outcomes, a figure that has notably regressed since April 2024. These trends underscore the critical need for targeted education emphasizing vaccine efficacy and safety grounded in robust clinical evidence.

Parallel to COVID-19 vaccine perceptions, attitudes toward other routine vaccines during pregnancy such as influenza, Tdap (tetanus, diphtheria, pertussis), and RSV (respiratory syncytial virus) remain subdued. Despite ongoing CDC recommendations endorsing these vaccines to protect maternal and neonatal health, less than half of survey participants would recommend flu or Tdap vaccines to pregnant persons, with only 31% open to endorsing the RSV vaccine during the prescribed gestational window of 32 to 36 weeks. Given the established morbidity associated with these infections during pregnancy, the disinclination to recommend pertinent immunizations elucidates a broader skepticism toward prenatal vaccination regimes.

The underpinning research for these observations stems from the 25th wave of the Annenberg Science and Public Health (ASAPH) survey panel, comprising 1,699 U.S. adults representing a statistically robust sample. Conducted in August 2025, the survey employed rigorous probability sampling to capture evolving public sentiments on critical health topics. The panel’s longitudinal methodology allows for tracking attitudinal shifts over time, revealing nuanced shifts in vaccine confidence that are instrumental for public health communication strategies.

This case exemplifies the complexity of public health policy when scientific data interfaces with political and social dynamics. The discordance between the CDC’s revised COVID-19 vaccine guidance and the prevailing scientific literature has precipitated legal challenges and criticism from the medical establishment, which continues to advocate for vaccination during pregnancy based on evidence demonstrating reduced maternal morbidity and neonatal protection. The discord highlights the potential repercussions of policy deviations on vaccine uptake and public trust.

It is imperative to consider the broader implications of this policy upheaval on maternal and infant health outcomes, especially as new viral variants continue to circulate and challenge existing immunity. The current trend of growing vaccine hesitancy among childbearing-age women could exacerbate vulnerabilities to COVID-19 and other infectious diseases, underlining the importance of clear, consistent, and science-driven messaging from health authorities.

In conclusion, the withdrawal of CDC support for COVID-19 vaccination in pregnant women marks a significant departure from prior policy grounded in comprehensive clinical research. The ensuing public hesitancy, as captured by APPC’s survey data, reflects the critical need for transparent communication that reconciles administrative directives with scientific evidence. As the medical community navigates these challenges, reinforcing vaccine confidence through education and engagement remains paramount to safeguarding maternal and child health in the evolving pandemic landscape.

Subject of Research: People

Article Title: [Not provided]

News Publication Date: [Not provided]

Web References:

• CDC COVID-19 Pregnancy Vaccination Guidelines: https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html
• Annenberg Public Policy Center ASAPH Survey Topline: https://www.annenbergpublicpolicycenter.org/wp-content/uploads/APPC_ASAPH_W25_vax_preg_topline_Sept_2025.pdf
• Annenberg Public Policy Research Methods: https://www.annenbergpublicpolicycenter.org/wp-content/uploads/X1102-APPC-National-Survey-Wave-24_Methods-Report_050525_Confidential.pdf
• CDC RSV Vaccine Guidance for Pregnant Women: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html

References:

• CDC Studies on COVID-19 Outcomes in Pregnant Women
• American Academy of Pediatrics lawsuit and public statements

Image Credits: Annenberg Public Policy Center

Keywords: Vaccination, COVID-19 vaccines, mRNA vaccines, Flu vaccines, Attenuated vaccines, Science policy, Biomedical policy, Public policy, Pregnancy, Public health, Human health, Obstetrics

Pregnancy uniquely modulates the immune system, creating a delicate balance between protecting maternal health and safeguarding fetal development. Early in the pandemic, data related to COVID-19’s effects on pregnancies were limited, resulting in hesitancy among policymakers to recommend vaccines for pregnant people unequivocally. This scientific uncertainty, coupled with historically rooted inequalities, has led to heterogeneous vaccine guidelines across countries and regions. Zavala et al.’s meticulous global analysis reveals how such disparities in vaccine policy reflect broader structural inequities embedded within healthcare systems, fundamentally challenging the principle of equitable healthcare access.

The study harnessed a multifaceted methodological framework, combining quantitative assessments of vaccine policies with qualitative evaluations of gender-sensitive healthcare policies in a diversity of socioeconomic contexts. By canvassing 60 countries across six continents, the research team cataloged varying approaches to vaccine prioritization, contraindications, and public health messaging specifically aimed at pregnant populations. The resultant dataset illuminated not only inconsistencies in policy adoption but also the variegated scientific rationales and socio-political influences shaping these decisions. This approach offers a granular understanding of how global health governance interacts with gender equity issues in pandemic response.

One of the study’s most salient findings concerns the lag in formal recognition of pregnant people as a priority group for COVID-19 vaccination. In many low- and middle-income countries, conservative caution prevailed, often deferring vaccination recommendations for pregnant individuals until sufficient safety data had accumulated post-authorization. While such prudence is understandable from a risk-benefit perspective, it inadvertently exacerbated vulnerability to infection and increased the risk of severe maternal morbidity and mortality. Zavala et al. highlight how such policy delays underscore an ethical tension between ensuring patient safety and addressing urgent needs in the face of an ongoing pandemic.

The researchers also delve into the communication strategies used to inform and engage pregnant people regarding vaccine safety and efficacy. Clear, gender-responsive messaging emerged as a cornerstone for fostering vaccine uptake and trust within this group. In many regions, however, official health communications were either inconsistent or failed to address specific concerns related to pregnancy, including potential impacts on fertility, placental health, and neonatal outcomes. This information vacuum has contributed to vaccine hesitancy, which the study suggests could be mitigated through targeted education campaigns grounded in participatory public health models.

Importantly, the study situates these vaccine policy inequities within the broader historical context of gender disparities in clinical research. Pregnant individuals have traditionally been excluded from clinical trials due to ethical complexities and liability concerns, leading to a paucity of high-quality evidence to guide treatment during pregnancy. Zavala and colleagues articulate how this structural exclusion has ripple effects extending to pandemic response efforts, where the lack of pregnancy-specific data hampers swift and confident policy formation. They advocate for a paradigm shift in biomedical research ethics that prioritizes the inclusion of pregnant people in clinical studies to enhance equity and scientific rigor.

At the crossroads of this analysis is the recognition that vaccine policy is not merely a biomedical issue but one intricately entangled with social determinants of health. The intersectionality of gender, socioeconomic status, ethnicity, and geography profoundly influences access to vaccines and quality prenatal care. For example, marginalized pregnant individuals in resource-limited settings often face compounded barriers, including limited healthcare infrastructure, misinformation, and systemic discrimination. Zavala et al.’s global perspective sheds light on these multifactorial challenges, reinforcing calls for intersectional approaches to public health interventions.

Moreover, the research highlights promising policy innovations emerging in certain countries that champion gender equity in vaccination strategies. A handful of nations have integrated pregnant people into early vaccine access groups and developed tailored outreach programs, combining clinical safety data with culturally competent communication efforts. These models serve as instructive examples demonstrating that policies grounded in equity principles can enhance both vaccine coverage and maternal-child health outcomes. The authors urge international health agencies to disseminate and support such best practices more widely.

The consequences of inequitable COVID-19 vaccine policies for pregnant people extend beyond immediate health implications. As the long-term sequelae of the pandemic unfold, delayed or denied vaccine access may contribute to sustained disparities in maternal morbidity and mortality rates. Additionally, the social repercussions of vaccine hesitancy and policy mistrust risk eroding confidence in healthcare systems among pregnant populations. Zavala et al.’s analysis serves as a clarion call to embed equity considerations systematically into future pandemic preparedness and response frameworks to prevent the repetition of such inequities.

Technological advancements in vaccine development, such as mRNA platforms, have revolutionized the speed and efficacy of immunization efforts. Yet, even with these breakthroughs, the equitable application of vaccines remains a formidable challenge. The study underscores that high scientific achievement does not automatically translate into equitable health outcomes without deliberate policy measures addressing structural barriers. This insight reinforces the necessity of integrating technological innovation with robust health systems strengthening aimed at marginalized groups, including pregnant people.

Furthermore, the authors discuss the role of transnational cooperation and global health governance in promoting equity in vaccine access. The COVID-19 pandemic has exposed weaknesses in current frameworks, with vaccine nationalism and intellectual property debates hampering widespread availability. Pregnant people, as a vulnerable demographic, often become invisible in these larger geopolitical struggles. Zavala et al. propose that embedding gender equity mandates within global health treaties and vaccine distribution agreements could safeguard pregnant populations in future health emergencies.

The ethical framework underpinning vaccination policies must also reconcile autonomy, beneficence, and justice, particularly in the context of pregnancy. The study explores how some countries have balanced individual choice with public health imperatives, fostering informed consent practices tailored to pregnant people’s concerns. This nuanced ethical approach contrasts with more paternalistic policies that may undermine trust and compliance. Zavala and colleagues contend that respecting pregnant people’s agency is crucial for ethical and effective vaccine delivery.

Beyond policy and ethics, the research touches upon the biomedical complexities of COVID-19 vaccination during pregnancy. Emerging evidence from observational studies and vaccine safety monitoring show promising outcomes, with no significant adverse effects on pregnancy or neonatal health. However, the authors emphasize that continued pharmacovigilance and large-scale data collection remain essential to confirm long-term safety profiles. This sustained research commitment is key to refining guidelines and diminishing hesitancy among pregnant populations.

The study ultimately advocates for a transformative agenda that interweaves gender equity into every stage of pandemic response — from research and development to policy implementation and community engagement. This holistic vision acknowledges that addressing disparities in vaccine access for pregnant people is both a scientific and social justice imperative. Zavala et al.’s global analysis is a landmark contribution that illuminates pathways toward equitable health futures where no demographic is left behind in the face of emergent infectious threats.

As the world prepares for future pandemics, the lessons drawn from this exhaustive study underscore the urgency of inclusive, gender-sensitive policies that protect pregnant people. By dismantling historical exclusions and embedding equity principles into health governance, societies can better safeguard maternal and fetal health through all stages of global health crises. The resonance of this research extends well beyond COVID-19, offering a blueprint for achieving just and effective healthcare policies worldwide.

Subject of Research: Gender equity in COVID-19 vaccine policies and their impact on pregnant people globally

Article Title: Gender equity and COVID-19 vaccine policies for pregnant people: a global analysis

Article References:
Zavala, E., Doggett, E., Nicklin, A. et al. Gender equity and COVID-19 vaccine policies for pregnant people: a global analysis. Int J Equity Health 24, 127 (2025). https://doi.org/10.1186/s12939-025-02497-0

Image Credits: AI Generated